323 related articles for article (PubMed ID: 20663909)
1. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer.
Cao L; Yu Y; Bilke S; Walker RL; Mayeenuddin LH; Azorsa DO; Yang F; Pineda M; Helman LJ; Meltzer PS
Cancer Res; 2010 Aug; 70(16):6497-508. PubMed ID: 20663909
[TBL] [Abstract][Full Text] [Related]
2. Carnitine palmitoyltransferase 1A (CPT1A): a transcriptional target of PAX3-FKHR and mediates PAX3-FKHR-dependent motility in alveolar rhabdomyosarcoma cells.
Liu L; Wang YD; Wu J; Cui J; Chen T
BMC Cancer; 2012 Apr; 12():154. PubMed ID: 22533991
[TBL] [Abstract][Full Text] [Related]
3. Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: focus on MYCN as a biologically relevant target.
Mercado GE; Xia SJ; Zhang C; Ahn EH; Gustafson DM; Laé M; Ladanyi M; Barr FG
Genes Chromosomes Cancer; 2008 Jun; 47(6):510-20. PubMed ID: 18335505
[TBL] [Abstract][Full Text] [Related]
4. PAX-FKHR function as pangenes by simultaneously inducing and inhibiting myogenesis.
Graf Finckenstein F; Shahbazian V; Davicioni E; Ren YX; Anderson MJ
Oncogene; 2008 Mar; 27(14):2004-14. PubMed ID: 17922034
[TBL] [Abstract][Full Text] [Related]
5. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3.
Fredericks WJ; Galili N; Mukhopadhyay S; Rovera G; Bennicelli J; Barr FG; Rauscher FJ
Mol Cell Biol; 1995 Mar; 15(3):1522-35. PubMed ID: 7862145
[TBL] [Abstract][Full Text] [Related]
6. AKT and PAX3-FKHR cooperation enforces myogenic differentiation blockade in alveolar rhabdomyosarcoma cell.
Jothi M; Nishijo K; Keller C; Mal AK
Cell Cycle; 2012 Mar; 11(5):895-908. PubMed ID: 22333587
[TBL] [Abstract][Full Text] [Related]
7. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma.
Barr FG
Oncogene; 2001 Sep; 20(40):5736-46. PubMed ID: 11607823
[TBL] [Abstract][Full Text] [Related]
8. High expression of the PAX3-FKHR oncoprotein is required to promote tumorigenesis of human myoblasts.
Xia SJ; Holder DD; Pawel BR; Zhang C; Barr FG
Am J Pathol; 2009 Dec; 175(6):2600-8. PubMed ID: 19893043
[TBL] [Abstract][Full Text] [Related]
9. Regulation of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
Ahn EH
Anticancer Res; 2013 May; 33(5):2029-35. PubMed ID: 23645752
[TBL] [Abstract][Full Text] [Related]
10. Nephroblastoma overexpressed (NOV/CCN3) gene: a paired-domain-specific PAX3-FKHR transcription target that promotes survival and motility in alveolar rhabdomyosarcoma cells.
Zhang Y; Wang C
Oncogene; 2011 Aug; 30(32):3549-62. PubMed ID: 21423212
[TBL] [Abstract][Full Text] [Related]
11. An engineered PAX3-KRAB transcriptional repressor inhibits the malignant phenotype of alveolar rhabdomyosarcoma cells harboring the endogenous PAX3-FKHR oncogene.
Fredericks WJ; Ayyanathan K; Herlyn M; Friedman JR; Rauscher FJ
Mol Cell Biol; 2000 Jul; 20(14):5019-31. PubMed ID: 10866659
[TBL] [Abstract][Full Text] [Related]
12. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.
Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C
Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427
[TBL] [Abstract][Full Text] [Related]
13. A genetic analysis of PAX3-FKHR, the oncogene of alveolar rhabdomyosarcoma.
Kempf BE; Vogt PK
Cell Growth Differ; 1999 Dec; 10(12):813-8. PubMed ID: 10616906
[TBL] [Abstract][Full Text] [Related]
14. Inducible short-term and stable long-term cell culture systems reveal that the PAX3-FKHR fusion oncoprotein regulates CXCR4, PAX3, and PAX7 expression.
Tomescu O; Xia SJ; Strezlecki D; Bennicelli JL; Ginsberg J; Pawel B; Barr FG
Lab Invest; 2004 Aug; 84(8):1060-70. PubMed ID: 15184910
[TBL] [Abstract][Full Text] [Related]
15. Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains.
Bennicelli JL; Fredericks WJ; Wilson RB; Rauscher FJ; Barr FG
Oncogene; 1995 Jul; 11(1):119-30. PubMed ID: 7624119
[TBL] [Abstract][Full Text] [Related]
16. Pax7-FKHR transcriptional activity is enhanced by transcriptionally repressed MyoD.
Olguín HC; Patzlaff NE; Olwin BB
J Cell Biochem; 2011 May; 112(5):1410-7. PubMed ID: 21321994
[TBL] [Abstract][Full Text] [Related]
17. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas.
Davicioni E; Finckenstein FG; Shahbazian V; Buckley JD; Triche TJ; Anderson MJ
Cancer Res; 2006 Jul; 66(14):6936-46. PubMed ID: 16849537
[TBL] [Abstract][Full Text] [Related]
18. Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions.
Barr FG; Qualman SJ; Macris MH; Melnyk N; Lawlor ER; Strzelecki DM; Triche TJ; Bridge JA; Sorensen PH
Cancer Res; 2002 Aug; 62(16):4704-10. PubMed ID: 12183429
[TBL] [Abstract][Full Text] [Related]
19. Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma.
Bennicelli JL; Edwards RH; Barr FG
Proc Natl Acad Sci U S A; 1996 May; 93(11):5455-9. PubMed ID: 8643596
[TBL] [Abstract][Full Text] [Related]
20. PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability.
Gryder BE; Yohe ME; Chou HC; Zhang X; Marques J; Wachtel M; Schaefer B; Sen N; Song Y; Gualtieri A; Pomella S; Rota R; Cleveland A; Wen X; Sindiri S; Wei JS; Barr FG; Das S; Andresson T; Guha R; Lal-Nag M; Ferrer M; Shern JF; Zhao K; Thomas CJ; Khan J
Cancer Discov; 2017 Aug; 7(8):884-899. PubMed ID: 28446439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
